{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:40:32Z","timestamp":1791949232505,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10549-017-4203-y","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T09:11:56Z","timestamp":1490087516000},"page":"507-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study"],"prefix":"10.1007","volume":"163","clinical-trial-number":[{"clinical-trial-number":"nct00036868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Konstantinos","family":"Tryfonidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"De Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Welnicka-Jaskiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Aalders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. S.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the EORTC- Breast Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"4203_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"4203_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"4203_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"4203_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"4203_CR5","volume-title":"Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer","author":"D Zardavas","year":"2013","unstructured":"Zardavas D, Cameron D, Krop I et al (2013) Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer. American Society of Clinical Oncology, Alexandria"},{"key":"4203_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119","journal-title":"N Engl J Med"},{"key":"4203_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734","journal-title":"N Engl J Med"},{"key":"4203_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw544","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, Costa A, Senkus E et al (2016) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. doi:10.1093\/annonc\/mdw544","journal-title":"Ann Oncol"},{"key":"4203_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1056\/NEJM197602192940801","volume":"294","author":"G Bonadonna","year":"1976","unstructured":"Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405\u2013410","journal-title":"N Engl J Med"},{"key":"4203_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.1983.1.1.2","volume":"1","author":"G Tancini","year":"1983","unstructured":"Tancini G, Bonadonna G, Valagussa P et al (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2\u201310","journal-title":"J Clin Oncol"},{"key":"4203_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20\u00a0years of follow-up. N Engl J Med 332:901\u2013906","journal-title":"N Engl J Med"},{"key":"4203_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/0277-5379(91)90259-G","volume":"27","author":"E Engelsman","year":"1991","unstructured":"Engelsman E, Klijn JC, Rubens RD et al (1991) \u201cClassical\u201d CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27:966\u2013970","journal-title":"Eur J Cancer"},{"key":"4203_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4048\/jbc.2014.17.1.33","volume":"17","author":"JH Ha","year":"2014","unstructured":"Ha JH, Seong MK, Kim EK et al (2014) Serial serum HER2 measurements for the detection of breast cancer recurrence in HER2-positive patients. J Breast Cancer 17:33\u201339","journal-title":"J Breast Cancer"},{"key":"4203_CR14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/172460080001500409","volume":"15","author":"MK Schwartz","year":"2000","unstructured":"Schwartz MK, Smith C, Schwartz DC et al (2000) Monitoring therapy by serum HER-2\/neu. Int J Biol Markers 15:324\u2013329","journal-title":"Int J Biol Markers"},{"key":"4203_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2307\/2533268","volume":"51","author":"J Bryant","year":"1995","unstructured":"Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372\u20131383","journal-title":"Biometrics"},{"key":"4203_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215\u20131221","journal-title":"J Clin Oncol"},{"key":"4203_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322\u2013329","journal-title":"J Clin Oncol"},{"key":"4203_CR18","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW et al (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525\u20133533","journal-title":"J Clin Oncol"},{"key":"4203_CR19","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107\u20134115","journal-title":"J Clin Oncol"},{"key":"4203_CR20","doi-asserted-by":"publisher","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ et al (2016) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2\u2013positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35:878\u2013884. doi:10.1200\/JCO.2015.65.7916","DOI":"10.1200\/JCO.2015.65.7916"},{"key":"4203_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1200\/JCO.1988.6.9.1377","volume":"6","author":"IF Tannock","year":"1988","unstructured":"Tannock IF, Boyd NF, DeBoer G et al (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377\u20131387","journal-title":"J Clin Oncol"},{"key":"4203_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3816\/CBC.2003.n.009","volume":"4","author":"M Jahanzeb","year":"2003","unstructured":"Jahanzeb M (2003) Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer 4:28\u201338","journal-title":"Clin Breast Cancer"},{"key":"4203_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","volume":"27","author":"G von Minckwitz","year":"2009","unstructured":"von Minckwitz G, du Bios A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03-05 study. J Clin Oncol 27:1999\u20132006","journal-title":"J Clin Oncol"},{"key":"4203_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377\u2013384","journal-title":"Lancet"},{"key":"4203_CR25","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","volume":"24","author":"N Robert","year":"2006","unstructured":"Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786\u20132792","journal-title":"J Clin Oncol"},{"key":"4203_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0009-9120(03)00026-2","volume":"36","author":"D Luftner","year":"2003","unstructured":"Luftner D, Luke C, Possinger K (2003) Serum HER-2\/neu in the management of breast cancer patients. Clin Biochem 36:233\u2013240","journal-title":"Clin Biochem"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-017-4203-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:43:57Z","timestamp":1628610237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-017-4203-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4203-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]},"assertion":[{"value":"9 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standard"}},{"value":"The authors declare none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}